<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622008</url>
  </required_header>
  <id_info>
    <org_study_id>W-4282-105</org_study_id>
    <nct_id>NCT03622008</nct_id>
  </id_info>
  <brief_title>To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind Study to Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) After Intravenous Administrations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinartis, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics (PK) of multiple IV doses of
      FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) administered every 8 hours (q8h) in healthy adult
      volunteers for 10 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will receive one of the following IV treatments as a q8h infusion (90 min) regimen for 10 days:
FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) (n=16)
Placebo (n=4)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by number of abnormal clinical laboratory test result</measure>
    <time_frame>every 8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the Maximum Concentration</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the Area Under the Curve [AUC]</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by number of abnormal physical examinations findings.</measure>
    <time_frame>every 8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by number of abnormal vital signs findings</measure>
    <time_frame>every 8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by number of abnormal 12 Lead ECG findings</measure>
    <time_frame>every 8 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Antibiotics Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>FEP-TAZ 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEP-TAZ 4 g</intervention_name>
    <description>FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days</description>
    <arm_group_label>FEP-TAZ 4 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body Mass Index (BMI) between 18 to 32 kg/m2 (both inclusive).

          -  Medical history without any major pathology.

          -  A sustained supine systolic blood pressure &lt;150 mm Hg or &gt;90 mm Hg or a supine
             diastolic blood pressure &lt;95 mm Hg or &gt;50 mm Hg at Screening or Check-in (Day -1).
             Blood pressure may be retested once in the supine position.

          -  Glomerular filtration rate (GFR) &gt; 80 mL/min, estimated by the Cockcroft-Gault
             equation.

        Exclusion Criteria:

          -  Use of cefepime and/or tazobactam within 60 days prior to study drug administration.

          -  History or evidence of clinically relevant pathology which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

